Atara Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary

Atara Biotherapeutics

08/05/2023 22:01

* Atara Biotherapeutics Inc  ATRA.OQ  reported a quarterly
adjusted loss of 72 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 39 cents per share.
    * Revenue fell 83.2% to $1.23 million from a year ago;
analysts
expected $30.68 million. 
    * Atara Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 72 cents​.
    * The mean earnings estimate of analysts had risen by
about 46.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Atara Biotherapeutics Inc shares had risen by 0.3% this
quarter and lost 11.3% so far this year.
    * The company reported a quarterly loss of $74.77 million.
    * Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $25.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.39          -0.72          Missed
 Dec. 31 2022      -0.51          -0.72          Missed
 Sep. 30 2022      -0.78          -0.82          Missed
 Jun. 30 2022      -0.93          -0.31          Beat